HER2-Low Breast Cancer: Where Are We?

Auteurs : Molinelli C, Jacobs F, Marchiò C, Pitto F, Cosso M, Spinaci S, de Azambuja E, Schettini F, Agostinetto E, Lambertini M
Jaar : 2022
Journal : Breast Care (Basel)
Volume : 17
Pagina's : 533-545

Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future.

Auteurs : Geukens T, Brandão M, Laenen A, Collignon J, Van Marcke C, Louviaux I, Demey W, Van Wambeke S, Schrijvers D, Lecomte S, Mebis J, Rutten A, Fontaine C, Lybaert W, Aspeslagh S, Goeminne JC, Van den Bulck H, Seront E, De Backer L, De Roock W, Ignatiadis M, Prenen H, Van Beckhoven D, Heijlen M, Verheezen J, Rottey S, Punie K, de Azambuja E
Jaar : 2022
Journal : ESMO Open
Volume : 7
Pagina's : 100610

Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer.

Auteurs : Agostinetto E, Jacobs F, Debien V, De Caluwé A, Pop CF, Catteau X, Aftimos P, de Azambuja E, Buisseret L
Jaar : 2022
Journal : Cancers (Basel)
Volume : 14

Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab.

Auteurs : Ligorio F, Di Cosimo S, Verderio P, Ciniselli CM, Pizzamiglio S, Castagnoli L, Dugo M, Galbardi B, Salgado R, Loi S, Michiels S, Triulzi T, Tagliabue E, El-Abed S, Izquierdo M, de Azambuja E, Nuciforo P, Huober J, Moscetti L, Janni W, Coccia-Portugal MA, Corsetto PA, Belfiore A, Lorenzini D, Daidone MG, Vingiani A, Gianni L, Pupa SM, Bianchini G, Pruneri G, Vernieri C
Jaar : 2022
Journal : J Natl Cancer Inst
Volume : 114
Pagina's : 1720-1727

Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel.

Auteurs : Arboleda B, Bartsch R, de Azambuja E, Hamilton E, Harbeck N, Klemp J, Knauer M, Kuemmel S, Mahtani R, Schwartzberg L, Villarreal-Garza C, Wolff A
Jaar : 2022
Journal : Oncologist
Volume : 27
Pagina's : 722-731

PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer.

Auteurs : Agostinetto E, Ameye L, Martel S, Aftimos P, Pondé N, Maurer C, El-Abed S, Wang Y, Vicente M, Chumsri S, Bliss J, Kroep J, Colleoni M, Petrelli F, Del Mastro L, Moreno-Aspitia A, Piccart M, Paesmans M, de Azambuja E, Lambertini M
Jaar : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pagina's : 87

Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis.

Auteurs : Martins-Branco D, Nader-Marta G, Tecic Vuger A, Debien V, Ameye L, Brandão M, Punie K, Loizidou A, Willard-Gallo K, Spilleboudt C, Awada A, Piccart M, de Azambuja E
Jaar : 2022
Journal : J Cancer Res Clin Oncol
Pagina's : 1-6

Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis.

Auteurs : Nader-Marta G, Martins-Branco D, Agostinetto E, Bruzzone M, Ceppi M, Danielli L, Lambertini M, Kotecki N, Awada A, de Azambuja E
Jaar : 2022
Journal : ESMO Open
Volume : 7
Pagina's : 100501

Anthracyclines in the treatment of patients with early breast cancer.

Auteurs : Guarneri V, de Azambuja E
Jaar : 2022
Journal : ESMO Open
Volume : 7
Pagina's : 100461

Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial.

Auteurs : Franzoi MA, Procter M, Twelves C, Ponde N, Eiger D, Emond O, Clark E, Parlier D, Guillaume S, Reaby L, de Azambuja E, Bines J
Jaar : 2022
Journal : Ecancermedicalscience
Volume : 16
Pagina's : 1379

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.

Auteurs : Piccart-Gebhart M, Procter M, Fumagalli D, de Azambuja E, Clark E, Ewer MS, Restuccia E, Jerusalem G, Dent S, Reaby L, Bonnefoi H, Krop I, Liu TW, Pienkowski T, Toi M, Wilcken N, Andersson M, Im YH, Tseng LM, Lueck HJ, Colleoni M, Monturus E, Sicoe M, Guillaume S, Bines J, Gelber Rd, Viale G, Thomssen C
Jaar : 2021
Journal : J Clin Oncol
Volume : 39
Pagina's : 1448-1457

Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer.

Auteurs : Franzoi MA, Agostinetto E, Perachino M, Del Mastro L, de Azambuja E, Vaz-Luis I, Partridge AH, Lambertini M
Jaar : 2021
Journal : Lancet Oncol
Volume : 22
Pagina's : e303-e313

Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network.

Auteurs : Morgan G, Tagliamento M, Lambertini M, Devnani B, Westphalen B, Dienstmann R, Bozovic-Spasojevic I, Calles A, Criscitiello C, Curioni A, Garcia AM, Lamarca A, Pilotto S, Scheffler M, Strijbos M, Wong R, de Azambuja E, Peters S
Jaar : 2021
Journal : ESMO Open
Volume : 6
Pagina's : 100104

OncoAlert Round Table Discussions: The Global COVID-19 Experience.

Auteurs : Morgan G, de Azambuja E, Punie K, Ades F, Heinrich K, Personeni N, Rahme R, Ferrara R, Pels K, Garassino M, von Bergwelt-Baildon M, Lopes G, Barlesi F, Choueiri TK, Burris H, Peters S
Jaar : 2021
Journal : JCO Glob Oncol
Volume : 7
Pagina's : 455-463

Emerging Therapeutics for Patients with Triple-Negative Breast Cancer.

Auteurs : Agostinetto E, Eiger D, Punie K, de Azambuja E
Jaar : 2021
Journal : Curr Oncol Rep
Volume : 23
Pagina's : 57

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).

Auteurs : Moreno-Aspitia A, Holmes EM, Jackisch C, de Azambuja E, Boyle F, Hillman DW, Korde L, Fumagalli D, Izquierdo MA, McCullough AE, Wolff AC, Pritchard KI, Untch M, Guillaume S, Ewer MS, Shao Z, Sim SH, Aziz Z, Demetriou G, Mehta AO, Andersson M, Toi M, Lang I, Xu B, Smith IE, Barrios CH, Baselga J, Gelber Rd, Piccart-Gebhart M
Jaar : 2021
Journal : Eur J Cancer
Volume : 148
Pagina's : 287-296

The Exciting New Field of HER2-Low Breast Cancer Treatment.

Auteurs : Eiger D, Agostinetto E, Saude Conde R, de Azambuja E
Jaar : 2021
Journal : Cancers (Basel)
Volume : 13

Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience.

Auteurs : Franzoi MA, Saude Conde R, Ferreira SC, Eiger D, Awada A, de Azambuja E
Jaar : 2021
Journal : Breast
Volume : 57
Pagina's : 86-94

CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis.

Auteurs : Agostinetto E, Vian L, Caparica R, Bruzzone M, Ceppi M, Lambertini M, Pondé N, de Azambuja E
Jaar : 2021
Journal : ESMO Open
Volume : 6
Pagina's : 100091

Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.

Auteurs : Agostinetto E, Eiger D, Lambertini M, Ceppi M, Bruzzone M, Pondé N, Plummer C, Awada A, Santoro A, Piccart-Gebhart M, de Azambuja E
Jaar : 2021
Journal : Eur J Cancer
Volume : 148
Pagina's : 76-91